Medicare AdvantageCoverageMedium impact
MA11.007b, Islet Cell Transplantation, including use of Donislecel-jujn (Lantidra)
Independence Blue Cross·Endocrinology, General Surgery·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA11.007b for Islet Cell Transplantation, including the new drug Donislecel-jujn (Lantidra), has been reissued with an effective date of March 5, 2025. This policy update affects coverage and billing for islet cell transplantation procedures and the associated drug therapy for diabetes treatment.
Action Required
By March 5, 2025: Billing team must review updated Medicare Advantage policy MA11.007b for islet cell transplantation and Donislecel-jujn (Lantidra) coverage criteria. Update prior authorization procedures and billing protocols for these diabetes treatment services. Verify coverage requirements with Medicare Advantage plans before scheduling procedures.